Physician

Sofia Palacio Cardenas, M.D.

According to 2025 Medicare claims, Sofia Cardenas, M.D. (NPI: 1063776086) practices hematology/oncology in the Albuquerque, NM market, with the plurality of this provider's patient population coming from Bernalillo, NM. This provider's primary affiliated billing organization is NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS, LTD. (NPI: 1164475232; TIN: 850367056) and primary practice location at 87109-4495. Cardenas is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Cardenas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 642 traditional Medicare patients, billed 96,165 HCPCS/CPT codes, and received $1,699,567 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,329 prescription claims across 417 beneficiaries totaling $4,743,376 in drug costs, led by Ibrance (Palbociclib). DME data shows 79 claims. Open Payments data shows 21 records totaling $714. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $65 to $4,743,376. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $1,045 to $5,714.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	261	26,532	$451,853
2020	592	119,811	$1,817,096
2021	623	104,863	$1,758,448
2022	821	116,207	$1,841,885
2023	662	114,777	$1,722,624
2024	642	96,165	$1,699,567

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	14	$65
2016	N/R	34	$3,036
2017	21	103	$317,542
2018	20	58	$204,921
2019	69	292	$422,945
2020	216	1,342	$1,417,402
2021	303	1,647	$2,480,611
2022	362	1,981	$3,322,455
2023	417	2,385	$4,206,550
2024	417	2,329	$4,743,376

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	35	$1,774
2022	N/R	49	$1,819
2023	N/R	57	$2,424
2024	N/R	79	$3,175

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	266	527	$128
96413	Administration of chemotherapy into vein, 1 hour or less	86	221	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	117	120	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	318	479	$12
96375	Injection of additional new drug or substance into vein	75	218	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	55	1,652	$934,037
Revlimid	Lenalidomide	29	812	$513,643
Lenalidomide	Lenalidomide	35	966	$474,356
Brukinsa	Zanubrutinib	28	840	$407,006
Verzenio	Abemaciclib	25	700	$379,987

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	26	$2,017
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	30	$510
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$473
K0001	Standard wheelchair	Y	N/R	11	$175

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$714	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sofia Palacio Cardenas, M.D.?

Tedicare shows public-source Medicare data for Sofia Palacio Cardenas, M.D. (NPI 1063776086), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sofia Palacio Cardenas, M.D. have ACO affiliation data?

Sofia Palacio Cardenas, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Sofia Palacio Cardenas, M.D.?

Sofia Palacio Cardenas, M.D. is linked to NEW MEXICO ONCOLOGY HEMATOLOGY CONSULTANTS, LTD. (billing NPI 1164475232) in the available physician profile data.

Does Sofia Palacio Cardenas, M.D. have Open Payments data?

Sofia Palacio Cardenas, M.D. has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.